Navigation Links
Choice of Derek H. Lee as Chief Financial and Corporate Development Officer Strengthens Talaris Advisors' Portfolio Design Business Model

Talaris to leverage Lee's venture capital expertise with more than 55 portfolio therapeutics, medical device and healthcare services companies.

Hopkinton, MA (PRWEB) March 8, 2010 -- Talaris Advisors, LLC, today announced the appointment of Derek H. Lee to the role of Chief Financial and Corporate Development Officer. Mr. Lee comes to Talaris from SV Life Sciences (SVLS), a leading healthcare venture capital firm with capital commitments of approximately $1.5 billion. He was responsible for directing strategic financial and investment planning that incorporated market considerations into the operational performance and financing requirements of more than 55 portfolio therapeutics, medical device and healthcare services companies.

"We are entering a new phase of biotech and pharma investment today where success will be determined by a company's ability to make smart analytical decisions about its drug development candidates and terminate programs early and quickly when they miss key competitive and capital indicators,” commented Mark J. Pykett, Chief Executive Officer. “In this regard, Derek brings a strong investor perspective to our operations. His experience in aligning development with exit strategies and realizing optimal exits are a key component of Talaris’ value proposition. As our Chief Financial and Corporate Development Officer, Derek's ability to conduct quantitative and qualitative analyses, identify key risks and opportunities in complex financial and valuation models, and facilitate negotiations will give us the corporate vantage point our valued clients and investors need.”

Derek brings a decade's worth of expertise in ensuring some of the best management teams in the industry achieved their investment objectives. His background includes a range of experiences, from private and public financing strategies, to M&A transactions, partnerships and deal structuring. Lee has prior experience working with the Global Healthcare Group at UBS Warburg and with the Healthcare Investment Banking Group at Salomon Smith Barney. He received his BS Finance from Bentley College.

Talaris Advisors works with biotech managers, companies and investors to optimize the use of capital and exit outcomes for drug development programs. Veteran team members, averaging 30 years of drug development experience, design and implement strategies that improve success rates, build multiple exit options and maximize investment returns for therapeutic drug assets. We align the commercial and regulatory requirements of drug candidates in development programs to reduce risk and time factors in pre-IND to Phase II proof-of-concept development, improving their odds for regulatory and commercial success. For investors, our integrated portfolio approach diversifies intrinsic investment risks. Members of the Talaris team have successfully completed more than 125 clinical studies and advanced more than 30 drug products through to the market. The company is headquartered in Hopkinton, Massachusetts. Please visit Talaris at

Media Contact:
Vicki Byatte
Talaris Advisors
Telephone: 508-497-2300 x 229    
Email: vbyatte(at)talarisadvisors(dot)com


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. BetterInvesting Magazine Releases May Stock to Study and Undervalued Stock Choices for Investors Informational and Educational Use
2. USHEALTH Career Agency Announces Americas Choice
3. Study: Choice between stroke-prevention procedures influenced by patient age
4. Nurtur Acquires ActivHealth and Wellness by Choice; Gains Exclusive Partnership with Duke University Center for Living
5. PCMA: Proposed Overhaul of FEHBP Pharmacy Benefit Would Undermine Cost-Saving Tools, Reduce Choices for 8 Million Americans
6. New Online Store Makes Buying Cosmetics a Healthy Choice
7. Dr Yaghouti of Global Laser Vision Receives Patient's Choice Award for 2009
8. Summit Medical Group Physician Named "Nurses Choice: Top Doctor"
9. Healthy Choice Shatters the Winter Mealtime Rut With 11 Delicious New Frozen Entrees
10. Morrisey Associates Partners With Total Living Choices (TLC) to Provide Software Value-Add to Customers
11. Security Choice Warns Against Dangers of Carbon Monoxide
Post Your Comments:
Related Image:
Choice of Derek H. Lee as Chief Financial and Corporate Development Officer Strengthens Talaris Advisors' Portfolio Design Business Model 
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... services for healthcare compliance program management, will showcase a range of technology and ... for Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 ...
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
(Date:10/12/2017)... ... 12, 2017 , ... Vohra Chief Medical Officer Dr. Shark ... skilled nursing facility medical directors and other clinicians at various events in October. ... "At many of these conferences we get to educate other physicians, facility nurses, ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Sept. 28, 2017 Cohen Veterans Bioscience and ... use of wearable and home sensors for real-time monitoring ... Signal Foundation, a nonprofit organization focused on disruptive health ... an affordable analytical system to record and integrate behavioral, ... ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform ... leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led ...
Breaking Medicine Technology: